Activation of the bone morphogenetic protein receptor by H11Kinase/Hsp22 promotes cardiac cell growth and survival

Circulation Research

Volumn 104, Issue 7, 2009, Pages 887-895

  Sui, Xiangzhen ^a   Li, Dan ^a   Qiu, Hongyu ^a   Gaussin, Vinciane ^a   Depre, Christophe ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Akt; Bone morphogenetic protein; Heat shock protein; Phosphatidylinositol 3 kinase

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; HEAT SHOCK PROTEIN 22; HYDROGEN PEROXIDE; NOGGIN; PHENYLALANINE H 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADIOISOTOPE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; BMP4 PROTEIN, MOUSE; BMPR1A PROTEIN, MOUSE; BMPR2 PROTEIN, MOUSE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; CARRIER PROTEIN; HEAT SHOCK PROTEIN; HSPB8 PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NOGGIN PROTEIN; PROTEIN SERINE THREONINE KINASE; RECEPTOR REGULATED SMAD PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL GROWTH; CELL ISOLATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART; HEART MUSCLE CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CELL CULTURE; CELL PROLIFERATION; ENZYMOLOGY; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CARRIER PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HEAT-SHOCK PROTEINS; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; SMAD PROTEINS, RECEPTOR-REGULATED; TRANSDUCTION, GENETIC;

EID: 65249153121     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.192328     Document Type: Article

References (33)

1. Smith C, Yu Y, Kulka M, Aurelian L. A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells. J Biol Chem. 2000;275: 25690-25699. (Pubitemid 30687072)
2. Depre C, Hase M, Gaussin V, Zajac A, Wang L, Hittinger L, Ghaleh B, Yu X, Kudej RK, Wagner T, Sadoshima J, Vatner SF. H11 kinase is a novel mediator of myocardial hypertrophy in vivo. Circ Res. 2002;91: 1007-1014.
3. Depre C, Tomlinson JE, Kudej RK, Gaussin V, Thompson E, Kim SJ, Vatner DE, Topper JN, Vatner SF. Gene program for cardiac cell survival induced by transient ischemia in conscious pig. Proc Natl Acad Sci U S A. 2001;98:9336-9341.
4. Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Program of cell survival underlying human and experimental hibernating myocar-dium. Circ Res. 2004;95:433-440.
5. Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, Ginion A, Shah A, Pelat M, Bertrand L, Wagner T, Gaussin V, Vatner SF. H11 kinase prevents myocardial infarction by pre-emptive preconditioning of the heart. Circ Res. 2006;98:280-288.
6. Danan IJ, Rashed ER, Depre C. Therapeutic potential of H11 kinase for the ischemic heart. Cardiovasc Drug Revs. 2007;25:14-29.
7. Cantley L. The phosphoinositide 3-kinase pathway. Science. 2002;296: 1655-1657.
8. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
9. Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone mor-phogenetic protein receptor ALK3. Proc Nat Acad Sci U S A. 2002;99: 2878-2883.
10. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783-2810.
11. Monzen K, Shiojima I, Hiroi Y, Kudoh S, Oka T, Takimoto E, Hayashi D, Hosoda T, Habara-Ohkubo A, Nakaoka T, Fujita T, Yazaki Y, Komuro I. Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol. 1999;19:7096-7105.
12. Gaussin V, Morley GE, Cox L, Zwijsen A, Vance KM, Emile L, Tian Y, Liu J, Hong C, Myers D, Conway SJ, Depre C, Mishina Y, Behringer RR, Hanks MC, Schneider MD, Huylebroeck D, Fishman GI, Burch JBE, Vatner SF. Alk3/Bmpr1a receptor is required for development of the atrioventricular canal into valves and annulus fibrosus. Circ Res. 2005; 97:219-226.
13. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X, Madura K, Depre C. Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res. 2008;77:497-505.
14. Abdellatif M, Packer S, Michael L, Zhang D, Charng M, Schneider M. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy. Mol Cell Biol. 1998;18:6729-6736.
15. Hedhli N, Lizano P, Hong C, Fritzky L, Dhar S, Liu H, Tian Y, Gao S, Madura K, F. Vatner S, Depre C. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol. 2008;295:H1385-H1393.
16. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord. 2006;7:51-65.
17. Hase M, Depre C, Vatner S, Sadoshima J. H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes. Biochem J. 2005;388:475-483.
18. Li B, Smith CC, Laing JM, Gober MD, Liu L, Aurelian L. Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1. Oncogene. 2007;26:3521-3531.
19. Gingery A, Bradley E, Pederson L, Ruan M, Horwood N, Oursler M. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res. 2008;314: 2725-2738.
20. Cheung P, Campbell D, Nebreda A, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J. 2003;22: 5793-5805.
21. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, Mihara M, Tsuchiya M, Matsumoto K. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem. 2003;278:18485-18490.
22. Hassel S, Eichner A, Yakymovych M, Hellman U, Knaus P, Souchelnytskyi S. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2004;4:1346-1358.
23. Kappé G, Franck E, Verschuure P, Boelens W, Leunissen J, de Jong W. The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones. 2003;8:53-61.
24. Fontaine JM, Sun X, Benndorf R, Welsh MJ. Interactions of Hsp22 (HSPB8) with hsp20, alphaB-crystallin, and HSPB3. Biochem Biophys Res Com. 2005;337:1006-1011.
25. Benndorf R, Sun X, Gilmont RR, Biederman KJ, Molloy MP, Goodmurphy CW, Cheng H, Andrews PC, Welsh MJ. HSP22, a new member of the small heat shock protein superfamily, interacts with mimic of phosphorylated HSP27 ((3D)HSP27). J Biol Chem. 2001;276:26753-26761.
26. Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, Schwartz JH, Borkan SC. Hsp27 inhibits Bax activation and apoptosis via a phospha-tidylinositol 3-kinase-dependent mechanism. J Biol Chem. 2008;283: 12305-12313.
27. Vitale J, Qiu H, Depre C. Pre-emptive conditioning of the ischemic heart. Cardiovasc Hematol Agents Med Chem. 2008;6:92-104.
28. Heinke J, Wehofsits L, Zhou Q, Zoeller C, Baar K-M, Helbing T, Laib A, Augustin H, Bode C, Patterson C, Moser M. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res. 2008;103:804-812.
29. Zhang N, Bradley A. Mice deficient for BMP2 are not viable and have defects in amnion/chorion and cardiac development. Development. 1996; 122:2977-2986.
30. Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995;9:2105-2116.
31. Ghosh-Choudhury N, Abboud SL, Mahimainathan L, Chandrasekar B, Choudhury GG. Phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2 (BMP-2)-induced myocyte enhancer factor 2A-dependent transcription of BMP-2 gene in cardiomyocyte precursor cells. J Biol Chem. 2003;278:21998-22005.
32. Izumi M, Fujio Y, Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Oshima Y, Nakaoka Y, Kishimoto T, Yamauchi-Takihara K, Hirota H. Bone morphogenetic protein-2 inhibits serum deprivation-induced apo-ptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J Biol Chem. 2001;276:31133-31141.
33. Ghosh-Choudhury N, Abboud S, Chandrasekar B, Ghosh Choudhury G. BMP-2 regulates cardiomyocyte contractility in a phosphatidylinositol 3 kinase-dependent manner. FEBS Lett. 2003;544:181-184.